Serum amyloid A, an acute phase protein, inhibits platelet activation

Shulamit Zimlichman, Abraham Danon, Ilana Nathan, Gabriel Mozes, Ruth Shainkin-Kestenbaum

Research output: Contribution to journalArticlepeer-review

76 Scopus citations


The effect of serum amyloid A, an acute phase protein, on platelet function was studied. Serum amyloid A was isolated and purified from sera of patients with recent trauma. Serum amyloid A inhibited thrombin-induced gel-fittered platelet aggregation. However, it did not inhibit aggregation induced by collagen or adenosine diphosphate, nor did it influence the aggregation of ptatelet-rich plasma activated with thrombin. Further studies of its effect on thrombin-induced activities showed that serum amyloid A, at concentrations of 25 to 100 μg/ml (which are found in mild acute events), suppressed the increase of cystosolic [Ca2+], thromboxane generation, and carbon 14-labeled serotonln release in a dose-dependent fashion. Serum amyloid A did not interfere with the clotting or amldolytic activities of thrombin. Therefore, the data suggest a protective role for serum amyloid A in thromboembolic dicease by specific interaction with thrombin-induced platelet activation. Amyloid A protein also markedly inhibited thrombin-induced platelet aggregation. Because amyloid A is homologous to the N-terminal portion of serum amyloid A, the observed activity probably resides in that part of the molecule. This finding may be of importance in localization of the active site on serum amyloid A.

Original languageEnglish
Pages (from-to)180-186
Number of pages7
JournalTranslational Research
Issue number2
StatePublished - 1 Jan 1990

ASJC Scopus subject areas

  • Pathology and Forensic Medicine


Dive into the research topics of 'Serum amyloid A, an acute phase protein, inhibits platelet activation'. Together they form a unique fingerprint.

Cite this